Merck hit with Phase III failure for Parkinson's drug
This article was originally published in Scrip
Merck & Co is discontinuing development of its adenosine A2a receptor antagonist, preladenant, for Parkinson's disease (PD) after an initial review of data from three separate Phase III trials failed to provide evidence of efficacy for the drug versus placebo.
You may also be interested in...
Emerging Company Profile: CEO Richard Miller, who co-founded Idec and Pharmacyclics, explains Corvus's approach of building a pipeline around an emerging target in cancer immunity that may be complementary to checkpoint inhibitors and other therapies.
Despite the long and troubled history of the molecule, Kyowa Hakko Kirin has persisted with the development of istradefylline for Parkinson's disease, but a new Phase III failure might be the last straw for the A2a antagonist.
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).